Stage 4 cancer strategies that truly make a difference
Stage 4 Cancer Strategies That Truly Make a DifferenceResearch on angiogenesis for stage 4 cancer – the method by which tumors attractblood vessels to nourish themselves was begun by Dr. Judah Folkman, who determinedthat a tumor placed in a lab container had a limited potential for growth. Moreover, heestablished that the micro vascular network for the cancer could be disrupted.Like so many great scientific minds with a new idea, Folkman was often ignored by hiscolleagues and peers. While it should be said that many agreed there was evidence ofnewly formed vessels – the dissenting assumption was that the detected inferior cellnetworks were merely a byproduct of dying tumor cells. Some years later Folkmancould prove that they, in fact, were actually being created by the cancer cells as ameans to deliver them there much-needed nutrients.Now consider this for a moment. The United States Government websiteHealthReport.gov contends that, “Nearly one out of two Americans born today will bediagnosed with cancer at some point in their lifetime. About 1,596,670 new cancer,cases are expected to be diagnosed in 2011 – and about 571,950 Americans areexpected to die of cancer, more than 1,500 people a day – and cancer is the secondmost common cause of death in the US, exceeded only by heart disease. In the US,cancer alone accounts for nearly 1 of every 4 deaths." Stage 4 cancer patients arealso growing in number due to late diagnosis and often non effect treatment methods.
With such a destructive epidemic facing us, one would think that new ideas andinnovation would be welcomed with open arms. Nevertheless, we regularly and haveeven come to expect the all-to-familiar pattern of contempt for ground-breakinginnovators and thinkers.In another example, devoted researcher Dr. Don Ingber was studying endothelial cellswhen one of his test samples became contaminated with a fungus. He was amazed tosee that in the presence of this fungus, the cells actually stopped growing. As fatewould have it, Ingber’s original position that angiogenesis could be inhibited wasultimately supported. Today anti-angiogenic drugs are a multibillion-dollarpharmaceutical industry and doctors like Folkan and Ingber, should receive far greatercommendation for their works – rather than the usual condemnation. Many o of theseanti-angiogenic chemotherapeutic drugs are used to manage stage 4 cancer patients.Anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib(Votrient®), and everolimus (Afinitor®) are typically prescribed in late-stage cancers inorder to slow growth. However, a simple agent like oxygen (non patentable) is an oftenoverlooked for the dominant anti-angiogenic agent that it is. In fact, oxygen metabolismerrors are involved in the cause and development of many cancers. These strategiesculminate with more than a decade of combining conventional and advanced naturalapproaches to treat cancer. Understanding the role of oxygen and using is correctly isvital for success, particularly when treating stage 4 cancer.In light of such grim aforementioned statistics, it is imperative that we must workcollectively and with open minds to defeat the venerable adversary called cancer andprovided better methods for tackling stage 4 cancer.Through all of the struggles some bright lights have emerged – and perhaps this onehas its place among the brightest - anti-antiogenic therapy. In simple terms, it isdesigned to starve stage 4 cancer from much needed nutrients thereby blocking itsdevelopment, growth, and spread.This is revolutionary when one considers that 90 percent of cancer patients succumb totheir disease because their cancer has spread beyond its original site (metasized) – thepicture of stage 4 cancer diagnosis. The fact that we may now inhibit tumorangiogenesis – is a quantum leap for treatment protocols.While such treatments are viewed as being in their fledgling states by conventionalinstitutions, Envita has already realized stunning success with them. In fact, it has beenfound that integrating these anti-angiogenic methods with traditional chemotherapy andradiation can work synergistically with the body and produce impressive results. Thesemethods seem to be very helpful for advanced stage 4 cancer patients as well.
Because of the incredible threat it imposes, there is no question that angiogenesisshould be blocked to stop tumor growth. In fact, without it, tumor growth is limited to aminiscule 2 mm in size. Envita’s specifically designed cancer therapies work by shuttingoff nutrients to the tumors and ultimately destroy the cancer cells that rely on them.In addition to this approach a protein known as VEGF (*vascular endothelial growthfactor) has been identified as the agent that stimulates angiogenesis. It has been foundthat a tumor releases VEGF for a variety of factors - one of which is triggered by a lackof oxygen, or hypoxia. This process is brought into being by the transcriptional factorHIF-1 (hypoxia inducible factor 1).One thing we can count on is that a tumor will always attempt to grow, even beyond thesupport of its existing blood supplies. As a result there is always a need for hypoxictissue on the tumor so it can create more VEGF. That alone is enough to suggest toEnvita that correcting a tumor’s oxygen metabolism will likely yield positive results.You see, without VEGF tumors simply cannot grow or spread. By introducing reactiveoxygen species, it is possible to potentiate other cancer treatments as they stimulate achange from anaerobic to aerobic that a tumor, by nature, will detest. Creating anenvironment that naturally repels stage 4 cancer is a critical method by which tofacilitate and maintain remission.But how can this be done effectively?Well, VEGF has been shown to bind to certain cells, called endothelials, of the nearbyblood vessels. These cells diverge and grow in the direction of the tumor forming new,albeit inferior blood vessels that actually rely on VEGF to survive. As fate would have it,they are not as difficult as one might think to detect. So, the goal then becomestargeting and destroying these rogue vessels while bolstering healthy ones. The endresult accelerates energy, cardiovascular stamina, and the patient’s overall endurance.It has been determined that VEGF is connected to a broad series of tumor types,including breast, ovarian, cervical, esophageal, lung, and cervical cancer, as well asglioblastoma multiforme and renal cell carcinoma. It would seem that VEGF emissionsmay also hinder the immune system’s ability to react and fight off the tumor - regularlyoccurring in stage 4 cancers.Remember, the immune system is our first and last defense against stage 4 cancers.While many patients believe that their cancer has been destroyed they often find outthat dormant metastasis was biding its time to strike. We can however attempt to thwartits efforts by correcting the body’s oxygen metabolism – thereby stopping angiogenesisin its tracks.
If you know anyone who has been diagnosed with cancer or has stage 4 cancer,please forward this article to them. We at Envita welcome you to contact us withquestions and invite you to watch our informative videos. You can also visit our PPMRsection to learn more about the power of our personalized medicine for cancer andchronic diseases. It is important information that may save lives. Education is the bestprescription.Take advantage of Envita’s Comprehensive Smart Oncology (link to Envita.com cancersection) which incorporates the foremost treatment approaches and synchronizes themwith aggressive natural therapies to help each patient far greater results. Visit Envita’sstage 4 cancer (link to Envita cancer section) therapies and strategies.References:*Judah Folkman <http://www.pbs.org/wgbh/nova/body/cancer-warrior.html > , <http://en.wikipedia.org/wiki/Judah_Folkman > *Stage 4 Cancer <http://en.wikipedia.org/wiki/Stage-4_cancer#Systems_of_staging > * Vascularendothelial growth factor<http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor>*HealthReform.gov<http://www.healthreform.gov/reports/fightingcancer/index.html>*American CancerSociety<http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf>